ALPA · Alpa Laboratories Ltd · Biotechnology & Drugs
ALPA · Alpa Laboratories Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
42.7% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹24 Cr
Revenue YoY
PAT YoY
-91.7%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
0.7
P/S (TTM)
1.2
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| ALPA (this stock) | 33.4 | 0.7 | +3.8% | +2.3% | 0.01 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedAlpa Laboratories Limited's FY2025-26 annual report highlights a strategic focus on maintaining financial stability through low borrowings and reinvesting profits into future growth initiatives, including R&D, market expansion, and potential acquisitions. The report emphasizes the company's commitment to quality manufacturing standards (WHO-GMP and ISO certified) and corporate governance, while noting a decline in sales and profits due to lower demand. The Board has prioritized internal development and operational strengthening over dividend distribution.
- Reinvestment of profits into R&D, market expansion, and potential acquisitions to drive long-term growth
- Commitment to maintaining WHO-GMP and ISO-certified manufacturing facilities
- Focus on corporate governance and transparency as core operational principles
- Decision to forgo dividends to conserve resources for future expansion
Key takeaway: Alpa Laboratories prioritizes long-term growth through strategic reinvestment and operational excellence, despite current challenges in sales and profit decline.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (3 items); Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
3 occurrencesRecent (last 12 months)
The auditor has issued a qualified opinion due to matters described in the Basis for Qualified Opinion paragraph.
Earlier (1-3 years ago)
The auditor issued a qualified opinion in the Basis for Qualified Opinion paragraph, stating that the standalone financial statements comply with Ind AS specified under Section 133 of the Act.
The auditor has issued a qualified opinion due to the possible effects of the matter described in the Basis for Qualified Opinion paragraph, indicating that the standalone financial statements may not fully comply with the Ind AS specified under Section 133 of the Act.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
Innovec Laboratories Private Limited (Medicure Nagpur) has a pending court case for recovery of ₹28,94,502.
Routine disclosures
Internal Control Weakness
3 occurrencesRecent (last 12 months)
Alpa Laboratories Limited reported significant changes in internal control over financial reporting and instances of significant fraud involving management or employees with significant roles in the internal control system to the Auditors and Audit Committee.
Earlier (1-3 years ago)
The auditor identifies a material uncertainty that may cast significant doubt on the appropriateness of the going concern assumption, indicating potential internal control weaknesses.
Older (3+ years ago)
Alpa Laboratories Limited has indicated to auditors and the audit committee about significant changes in internal control over financial reporting, changes in accounting policies, and instances of significant fraud involving management or employees with significant roles in the internal control system.
Contingent Liability
6 occurrencesRecent (last 12 months)
The company has contingent liabilities including disputed Sales Tax Dues and Income Tax Dues, and guarantees to banks and financial institutions as of 31st March, 2026.
Earlier (1-3 years ago)
The company has disputed Sales Tax Dues and Income Tax Dues as contingent liabilities, with amounts not acknowledged as debts.
The company has contingent liabilities amounting to ₹7.07 Lacs as of 31st March, 2024 and ₹6.26 Lacs as of 31st March, 2023.
Older (3+ years ago)
The company has contingent liabilities including disputed sales tax dues, disputed income tax dues, and guarantees to banks and financial institutions. The amounts for these liabilities are not specified in the excerpt.
The company has contingent liabilities related to disputed sales tax dues and disputed income tax dues as of the reporting period.
The company has contingent liabilities of ₹3.66 lacs as at 31st March, 2021 and ₹6.08 lacs as at 31st March, 2020.
Related-Party Transaction
2 occurrencesEarlier (1-3 years ago)
The company has disclosed transactions with related parties including investments in Seabright Landmark Projects LLP, profit sharing with Wealthpile Trading LLP, and remuneration to directors and non-executive directors.
Older (3+ years ago)
The company has disclosed transactions with related parties, including purchases from Aurum Enterprises (relative of a director) and receivables from relatives of executive directors, as well as compensation for executive directors and non-executive directors.
Statutory dues in dispute
1 occurrenceEarlier (1-3 years ago)
The company has outstanding income-tax, sales-tax, and value added tax dues due to disputes, with amounts pending in appeals and litigation before authorities in Madhya Pradesh.
Management & Board Governance
1 occurrenceRecent (last 12 months)
The Company Secretary and Compliance Officer, Ms. Srashti Chopra, resigned on 25th March 2026. Subsequently, Ms. Yashoda Patidar was appointed on 11th April 2026 and resigned on 26th July 2026. The company is currently identifying a new candidate for the position.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
2.29% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).